Cellenkos, Inc. logo

Cellenkos, Inc.

Developing off-the-shelf T regulatory (Treg) cell therapies for rare inflammatory diseases and autoimmune disorders.

14 employees · est. 2016

VS
Tr1X logo

Tr1X

Engineering cures for patients with autoimmune & inflammatory diseases.

46 employees · est. 2018 · San Diego, United States

Cellenkos, Inc. is the older company (2016 vs 2018).

Side-by-Side Comparison

Cellenkos, Inc. Tr1X
Founded
2016 older 2018
Headquarters
Not tracked yet San Diego, United States
Employees
14 46
Industry
Biotechnology Biotechnology, Health Care, Life Sciences
Funding Stage
Series A Unknown
Total Funding
$15.00M $125.00M
Funding Rounds
1 3
Services
Development of T-Regulatory Cell Therapies, Clinical Trial Management, Allogeneic Therapy Research Not tracked yet
Target Customers
Patients with Autoimmune Diseases, Healthcare Providers, Biotechnology Researchers, Pharmaceutical Companies Not tracked yet
Taxonomy
Treg Cell Therapy, Allogeneic Products, Inflammatory Diseases, Autoimmune Disorders, CRANE Platform, Umbilical Cord Blood, Rare Autoimmune Blood Disorders, Cell Therapy, Immunomodulation, Oncology, Neuro-degenerative Diseases, Inflammatory Pulmonary Disease, MD Anderson Cancer Center, Clinical-Stage Cellular Immunotherapies, Autoimmune Diseases, Inflammatory Diseases, Immune System, Cell Therapy, Proprietary Platform, Immune Modulation, Homeostasis, Tolerance, La Jolla, California
Website
cellenkosinc.com tr1x.bio
Cellenkos, Inc. logo

About Cellenkos, Inc.

Cellenkos, Inc., established in 2016, is a clinical stage biotechnology company with a focus on developing off-the-shelf T regulatory (Treg) cell therapies for rare inflammatory and autoimmune diseases. Pioneered from a proprietary platform licensed from MD Anderson Cancer Center, Cellenkos leverage...

Tr1X logo

About Tr1X

Tr1X Inc. is a biotechnology company founded in 2018, with headquarters in La Jolla, CA. The company's slogan "Engineering cures for patients with autoimmune & inflammatory diseases" encapsulates its dedication to developing novel cellular immunotherapies for patients in need. Tr1X specializes in le...

We will tell you when either one moves

BounceWatch watches Cellenkos, Inc. and Tr1X for new funding, fast hiring, new executives and a change of software vendor. When one happens, we email you the same day.

Watch both — free

Funding, hiring, leadership and stack changes at Cellenkos, Inc. and Tr1X — by email.

Frequently Asked Questions

Cellenkos, Inc. — Developing off-the-shelf T regulatory (Treg) cell therapies for rare inflammatory diseases and autoimmune disorders.. Tr1X — Engineering cures for patients with autoimmune & inflammatory diseases.. Both companies operate in related markets but may differ in funding stage, team size, and product focus.
Cellenkos, Inc. has raised $15.00M while Tr1X has raised $125.00M.
Cellenkos, Inc. and Tr1X operate in overlapping markets and are frequently compared. Track both companies on Bounce Watch to monitor their growth signals in real time.

Compare Cellenkos, Inc. with someone else

Start typing a company name or domain.

Compiled from the BounceWatch company index. We last looked at Cellenkos, Inc. on 2 Apr 2026, and Tr1X on 9 Jun 2026. Where a field is blank here, it means we have not recorded it — not that the answer is zero. How we source and date this.

One analytics cookie (Google Analytics). Cookie Policy